US20070221535A1 - Package for multiple dose inhalators having optimised emptying properties - Google Patents

Package for multiple dose inhalators having optimised emptying properties Download PDF

Info

Publication number
US20070221535A1
US20070221535A1 US11/691,882 US69188207A US2007221535A1 US 20070221535 A1 US20070221535 A1 US 20070221535A1 US 69188207 A US69188207 A US 69188207A US 2007221535 A1 US2007221535 A1 US 2007221535A1
Authority
US
United States
Prior art keywords
amino
phenyl
capsule
package
quinazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/691,882
Inventor
Herbert Wachtel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20070221535A1 publication Critical patent/US20070221535A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
    • A61M15/0048—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged in a plane, e.g. on diskettes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
    • A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Definitions

  • the invention relates to a package for pharmaceutical compositions, mixtures or formulations for use in a powder inhaler.
  • the multi-dose powder inhalers contain the pharmaceutical composition, mixture or formulation either in the form of a powder supply from which the single dose is taken from a well by means of a built-in metering unit, or pre-metered packaged single doses which are either stored together in the device (e.g., in the form of packaged amounts in blisters) or are placed individually in the device for use (e.g., in the form of capsules).
  • the manner of packaging in which the powder formulation is present in the device is critical to the quality of the product and hence to its suitability for use by inhalation.
  • a chief objective of the packaging is to keep the chemical composition of the atmosphere inside the packaging constant, in order to prevent physical or chemical changes to the pharmaceutical composition, mixture or formulation, or to stabilise them.
  • in-use stability a distinction is made between stability directed to the short term, which the pharmaceutical composition, mixture or formulation has to have per se, even if it is not adequately protected by the packaging (“in-use stability”) and the long-term stability, i.e., the stability which has to be guaranteed for as long as the pharmaceutical composition, mixture or formulation is contained in the unopened package.
  • fine particle dose refers to the dose that reaches the patient's lungs.
  • the fine particle dose is influenced by the interactions of the micronised particles of active substance with one another and also the interactions with the excipients.
  • a package it is also necessary for a package to have a shape and an opening pattern (i.e., the places in the packaging which allow the blister to be opened by piercing or cutting) which enable an optimum air supply and hence optimum delivery of the pharmaceutical composition, mixture, or formulation.
  • Examples of multi-dose powder inhalers are known in the art. They are known for example from EP 0 703 800 B1 or EP 0 911 047 A1, which disclose a powder inhaler consisting of a cup-shaped lower part and an equally cup-shaped lid. After placing the capsule in the capsule holder, the patient can press an actuating member which is movable from a resting position and thereby interacts with at least one pin that can be pressed into the capsule holder. The capsule is pierced by the pin or pins and the drug is released.
  • DE 3348370 and DE 3336486 further disclose inhalers which contain a disc-shaped blister pack comprising a number of wells arranged in a circle.
  • the individual wells each contain a dose of a medicament powder intended for inhalation.
  • the wells are closed off on both sides by a sealing film, for example.
  • An air channel connects the opened well with the mouthpiece of the inhaler.
  • the inhaler of DE 3336486 will be described in more detail. It comprises a housing in which there is a chamber (supply chamber) comprising an air inlet and in which there is a disc-shaped round blister with medicament pouches packed therein.
  • the blister is loosely connected to a rotatable round disc.
  • Around the disc are formed holes which are axially in contact with the medicament pouches, i.e., the pouches and holes are located above and below one another.
  • the chamber has an air outlet.
  • the inhaler also has a piston which is arranged so that it can open a pouch of medicament by piercing it, so that the medicament is released into the chamber and can be breathed in through a mouthpiece.
  • the primary packaging is characterized in that it is in direct contact with the inhalable formulation.
  • the primary packaging may optionally be surrounded by a second, outer protection, the secondary packaging.
  • the primary packaging may be, for example, a capsule, a solid or flexible blister with wells or a disc comprising wells.
  • the secondary packaging may be a blister, a pouch, a bag or other container.
  • the secondary packaging generally totally encloses the primary packaging. Secondary packaging is used particularly when the primary packaging does not provide adequate protection from moisture.
  • the primary packaging and optionally the secondary packaging have the task of protecting the active substance and also the entire inhalable formulation from chemical or physical change, so that it remains stable for long periods.
  • the physical changes in question may be, in particular, changes which might affect the delivery of the intended dose of fine particles.
  • the choice of a suitable material for the packaging is determined by two factors. On the one hand the material must be able to perform the protective function required. On the other hand the material must be such that the packaging can be made into the form needed for use in the powder inhaler and can perform the function expected of it.
  • the problem underlying the present invention is to optimise the shape of the packaging, the piercing pattern of the packaging and the fill level of a pharmaceutical composition, mixture or formulation, so as to improve the delivery of a pharmaceutical composition, mixture or formulation.
  • the present invention therefore relates to packages for inhalable powders, which are optimised in their shape, piercing pattern and fill level with a pharmaceutical composition, mixture or formulation.
  • FIGS. 1-10 show, by way of example, the different shapes of a capsule or of an individual well of a blister (known over all as packaging means) and the corresponding piercing positions.
  • FIG. 1 sphere or hemisphere, 5 hole-shaped inlet openings, 1 outlet
  • FIG. 2 sphere or hemisphere, 4 hole-shaped inlet openings, 1 outlet
  • FIG. 3 oval shape, 6 hole-shaped inlet openings, 1 outlet
  • FIG. 4 oval shape, 5 hole-shaped inlet openings, asymmetrical, 1 outlet
  • FIG. 5 oval shape, 3 hole-shaped inlet openings, asymmetrical, 1 outlet
  • FIG. 7 bone-shaped, 2 ⁇ 3 hole-shaped inlet openings, 1 outlet
  • FIG. 8 bone-shaped, 2 ⁇ 2 hole-shaped inlet openings, asymmetrical, 1 outlet
  • FIG. 9 figure-of-eight shape, 2 ⁇ 3 hole-shaped inlet openings, 1 outlet
  • FIG. 10 figure-of-eight shape, 2 ⁇ 2 hole-shaped inlet openings, asymmetrical, 1 outlet
  • FIG. 11 teardrop-shape, 3 hole-shaped inlet openings, 1 outlet
  • FIG. 12 teardrop-shape, 4 hole-shaped inlet openings, 1 outlet
  • FIG. 13 teardrop-shape, crescent-shaped inlet, 1 outlet
  • the invention relates to optimised packages as described above which allow improved air flow and hence improved delivery of a pharmaceutical composition, mixture or formulation by virtue of the shape of their opening pattern in their piercing pattern and the fill level with the pharmaceutical composition, mixture or formulation.
  • the packages consist of a capsule, a blister, a blister disc or a blister strip. These different forms (with the exception of the capsules) will hereinafter be referred to over all as blisters.
  • the capsule generally consists of two parts, a capsule body (body) and a capsule cap (cap), which fit telescopically inside one another.
  • body body
  • capsule cap cap
  • multi-part capsules are also known. It is preferable to use size 2-4 capsules, most preferably size 3 capsules.
  • the capsule material is non-digestible plastics or gelatine, particularly hard gelatine.
  • the blister disc may be, for example, a cylinder-like disc up to 5 mm high and up to 15 cm in diameter. In the disc are depressions or holes (wells) formed perpendicularly to the plane of the disc.
  • a disc of this kind may for example be placed in an inhaler according to DE 3348370 or DE 3336486.
  • An inhaler of this kind has a housing which contains the disc-shaped round blister with medicament pouches packed therein.
  • the inhaler comprises, inter alia, a pin which is arranged so that it can open one medicament pouch, so that the medicament is released into the chamber and can be breathed in through a mouthpiece.
  • the shape of the package according to the invention including the shape of the well is fundamentally determined by the powder inhaler which is to be used.
  • the packaging is teardrop-shaped or oval or in the shape of a figure of eight.
  • the inflow surfaces and outflow surface(s) are as far away from one another as possible.
  • the package which is a blister first of all comprises a base element consisting of a thermoplastic plastics and at least two wells separated from one another by a web.
  • the wells are open at least on one side, possible on two opposing sides. These openings are closed off in the packaging ready for use, e.g., by means of a sealing foil which is attached to the base element.
  • the package may consist of standard commercial materials. Preferably, it consists of a plastics material. Most preferably, the materials used as plastics selected from among the thermoplastic polymers such as, e.g., polystyrenes, polyolefins, polyamides, polyvinyl chlorides, polyethylenes, polycarbonate, polyester, polypropylene, polyethylene terephthalate or polyurethane. These have the necessary rigidity or mobility to enable them to perform the mechanical tasks of the primary packaging. Also suitable are, for example, natural substances such as gelatine or composite materials of plastics and metals, such as aluminium.
  • the thermoplastic polymers such as, e.g., polystyrenes, polyolefins, polyamides, polyvinyl chlorides, polyethylenes, polycarbonate, polyester, polypropylene, polyethylene terephthalate or polyurethane.
  • these have the necessary rigidity or mobility to enable them to perform the mechanical tasks of the primary packaging.
  • natural substances such as gelatine
  • all the walls of the well should consist of the same material.
  • at least the wall that closes off the opening may be made of a different material from the other walls.
  • composition or processing can be found in the prior art, particularly EP599690, EP432438 or EP400460.
  • the fill level of the pharmaceutical composition, mixture or formulation in the package can be optimised and will depend on the flowability of the pharmaceutical composition, mixture or formulation.
  • flowability indicates the ability of the pharmaceutical composition, mixture or formulation to flow easily as a loose material.
  • ⁇ 1 is the solidification tension and ⁇ c is the bulk strength. Normally the flowability is determined using a ring shear device.
  • the flowability accords with the following: 4 ⁇ ff c >1.
  • packages are used which are partly filled, such that there is a free passage for air between at least one inlet opening and an outlet opening.
  • the formula for the flowability is 4 ⁇ ff c .
  • packages which are partly filled are used, such that there is a free passage of air between at least one inlet opening and an outlet opening, or which are completely filled so that an advantageous (simple and inexpensive) filling process can be used.
  • the fill volume is determined by the shape of the packaging and there is no need for any special metering process.
  • compositions, formulations or mixtures include all the inhalable compounds, such as, e.g., inhalable macromolecules, as disclosed in EP 1 003 478.
  • W is a pharmacologically active substance and is selected (for example) from among the betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, H1-antihistamines, PAF-antagonists, and P13-kinase inhibitors.
  • W might be, for example:
  • the compounds used as betamimetics are preferably compounds selected from among albuterol, arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmefamol, salmeterol, soterenol, sulphonterol, terbutaline, tiaramide, tolubuterol, zinterol, CHF-1035, HOKU-81, KUL-1248, and
  • the anticholinergics used are preferably compounds selected from among the tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, trospium salts, preferably the chloride salt, tolterodine.
  • the cations are the pharmacologically active constituents.
  • the above-mentioned salts may preferably contain the chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulphonate, while chloride, bromide, iodide, sulphate, methanesulphonate or p-toluenesulphonate are preferred as counter-ions.
  • the chlorides, bromides, iodides, and methanesulphonates are particularly preferred.
  • X ⁇ denotes an anion with a single negative charge, preferably an anion selected from among the fluoride, chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, preferably an anion with a single negative charge, particularly preferably an anion selected from among the fluoride, chloride, bromide, methanesulphonate and p-toluenesulphonate, particularly preferably bromide, optionally in the form of the racemates, enantiomers or hydrates thereof.
  • corticosteroids it is preferable to use compounds selected from among beclomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone, RPR-106541, NS-126, ST-26, and
  • PDE4-inhibitors which may be used are preferably compounds selected from among enprofyllin, theophyllin, roflumilast, ariflo (cilomilast), tofimilast, pumafentrin, lirimilast, arofyllin, atizoram, D-4418, Bay-198004, BY343, CP-325.366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-11294A, C1-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370, and
  • the LTD4-antagonists used are preferably compounds selected from among montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001,MEN-91507 (LM-1507), VUF-5078, VUF-K-8707, L-733321 and
  • EGFR-inhibitors which may be used are preferably compounds selected from among cetuximab, trastuzumab, ABX-EGF, Mab ICR-62, and
  • the dopamine agonists used are preferably compounds selected from among bromocriptin, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexol, roxindol, ropinirol, talipexol, tergurid, and viozan, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof.
  • these acid addition salts are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate, and hydro-p-toluenesulphonate.
  • H1-Antihistamines which may be used are preferably compounds selected from among epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bamipine, cexchlorpheniramine, pheniramine, doxylamine, chlorophenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine, and meclozine, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates, or hydrates thereof.
  • these acid addition salts are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate, and hydro-p-toluenesulphonate.
  • the compounds may come from the groups of ergot alkaloid derivatives, the triptans, the CGRP-inhibitors, the phosphodiesterase-V inhibitors, optionally in the form of the racemates, enantiomers, or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts, the solvates, and/or hydrates thereof.
  • Examples of ergot alkaloid derivatives are dihydroergotamine and ergotamine.
  • suitable substances include pharmaceutical compositions, pharmaceutical formulations and mixtures with the above-mentioned active substances, as well as the salts and esters thereof and combinations of these active substances, salts, and esters.
  • the emptying properties were determined using a standard powder (glass beads) by measuring the time taken for emptying a given constant flow by volume (corresponding to 10 L/min of air).
  • Table 1 shows the emptying time of the different shapes of capsules or blisters.
  • the inlet openings are shown in the drawings as small circles while the outlet openings are shown as large circles.
  • the active substance in micronised form has a particle size of 1-5 ⁇ m.
  • the powder mixture also contains lactose 200 m.
  • a well of a package which has an optimum air flow by reason of its shape and opening patter has significantly enhanced emptying properties.
  • the following formula applies to the ratio V (sum of the inflow surfaces divided by the sum of the outflow surfaces): 0.5 ⁇ V ⁇ 2.
  • the sum of the inflow surfaces should be equal to the sum of the outflow surfaces.

Abstract

The invention relates to a package for pharmaceutical compositions, mixtures or formulations for use in a powder inhaler.

Description

    BACKGROUND OF THE INVENTION
  • This application claims priority of DE 10 2006 014 434, which application is incorporated herein by reference in its entirety.
  • 1. Field of the Invention
  • The invention relates to a package for pharmaceutical compositions, mixtures or formulations for use in a powder inhaler.
  • 2. Description of the Prior Art
  • Medical aerosol therapy intended for pulmonary inhalation using nebulisers, metered-dose aerosols or powder inhalers plays an important part in the treatment of numerous lung diseases.
  • In the field of powder inhalers, single-dose and multi-dose devices are known. The multi-dose powder inhalers contain the pharmaceutical composition, mixture or formulation either in the form of a powder supply from which the single dose is taken from a well by means of a built-in metering unit, or pre-metered packaged single doses which are either stored together in the device (e.g., in the form of packaged amounts in blisters) or are placed individually in the device for use (e.g., in the form of capsules).
  • In multi-dose powder inhalers, in particular, the manner of packaging in which the powder formulation is present in the device is critical to the quality of the product and hence to its suitability for use by inhalation.
  • Therefore, a chief objective of the packaging is to keep the chemical composition of the atmosphere inside the packaging constant, in order to prevent physical or chemical changes to the pharmaceutical composition, mixture or formulation, or to stabilise them.
  • In this context a distinction is made between stability directed to the short term, which the pharmaceutical composition, mixture or formulation has to have per se, even if it is not adequately protected by the packaging (“in-use stability”) and the long-term stability, i.e., the stability which has to be guaranteed for as long as the pharmaceutical composition, mixture or formulation is contained in the unopened package.
  • It is also important that the patient receives the correct dose of the inhalable formulation on inhaling.
  • The term “fine particle dose” refers to the dose that reaches the patient's lungs. The fine particle dose is influenced by the interactions of the micronised particles of active substance with one another and also the interactions with the excipients.
  • It is also known that particularly as a result of variations in the level of moisture in the interior of the packaging these interactions may increase such that the fine particle dose is significantly reduced. Such changes include the penetration of water into the package and also the elimination of water from the inside of the package.
  • It is also necessary for a package to have a shape and an opening pattern (i.e., the places in the packaging which allow the blister to be opened by piercing or cutting) which enable an optimum air supply and hence optimum delivery of the pharmaceutical composition, mixture, or formulation.
  • Examples of multi-dose powder inhalers are known in the art. They are known for example from EP 0 703 800 B1 or EP 0 911 047 A1, which disclose a powder inhaler consisting of a cup-shaped lower part and an equally cup-shaped lid. After placing the capsule in the capsule holder, the patient can press an actuating member which is movable from a resting position and thereby interacts with at least one pin that can be pressed into the capsule holder. The capsule is pierced by the pin or pins and the drug is released. Thus, for example, DE 3348370 and DE 3336486 further disclose inhalers which contain a disc-shaped blister pack comprising a number of wells arranged in a circle. The individual wells each contain a dose of a medicament powder intended for inhalation. The wells are closed off on both sides by a sealing film, for example. To deliver the medicament powder the cavity is opened. An air channel connects the opened well with the mouthpiece of the inhaler. By way of example the inhaler of DE 3336486 will be described in more detail. It comprises a housing in which there is a chamber (supply chamber) comprising an air inlet and in which there is a disc-shaped round blister with medicament pouches packed therein. The blister is loosely connected to a rotatable round disc. Around the disc are formed holes which are axially in contact with the medicament pouches, i.e., the pouches and holes are located above and below one another. The chamber has an air outlet. The inhaler also has a piston which is arranged so that it can open a pouch of medicament by piercing it, so that the medicament is released into the chamber and can be breathed in through a mouthpiece. Reference is made to the drawings in the patent application and US patent specification.
  • With regard to the packaging of medicament powders, a distinction is made between the primary packaging and the secondary packaging. The primary packaging is characterized in that it is in direct contact with the inhalable formulation. The primary packaging may optionally be surrounded by a second, outer protection, the secondary packaging. The primary packaging may be, for example, a capsule, a solid or flexible blister with wells or a disc comprising wells.
  • The secondary packaging may be a blister, a pouch, a bag or other container. The secondary packaging generally totally encloses the primary packaging. Secondary packaging is used particularly when the primary packaging does not provide adequate protection from moisture.
  • The primary packaging and optionally the secondary packaging have the task of protecting the active substance and also the entire inhalable formulation from chemical or physical change, so that it remains stable for long periods. The physical changes in question may be, in particular, changes which might affect the delivery of the intended dose of fine particles.
  • The choice of a suitable material for the packaging is determined by two factors. On the one hand the material must be able to perform the protective function required. On the other hand the material must be such that the packaging can be made into the form needed for use in the powder inhaler and can perform the function expected of it.
  • The problem underlying the present invention is to optimise the shape of the packaging, the piercing pattern of the packaging and the fill level of a pharmaceutical composition, mixture or formulation, so as to improve the delivery of a pharmaceutical composition, mixture or formulation.
    • SUMMARY OF THE INVENTION
  • This problem is solved by a package according to claim 1. Advantageous further features are the subject-matter of the subsidiary claims.
  • The present invention therefore relates to packages for inhalable powders, which are optimised in their shape, piercing pattern and fill level with a pharmaceutical composition, mixture or formulation.
    • BRIEF DESCRIPTION OF THE INVENTION
  • The Figures show, by way of example, the different shapes of a capsule or of an individual well of a blister (known over all as packaging means) and the corresponding piercing positions.
  • The Figures serve to illustrate the invention without restricting its scope.
  • FIG. 1: sphere or hemisphere, 5 hole-shaped inlet openings, 1 outlet
  • FIG. 2: sphere or hemisphere, 4 hole-shaped inlet openings, 1 outlet
  • FIG. 3: oval shape, 6 hole-shaped inlet openings, 1 outlet
  • FIG. 4: oval shape, 5 hole-shaped inlet openings, asymmetrical, 1 outlet
  • FIG. 5: oval shape, 3 hole-shaped inlet openings, asymmetrical, 1 outlet
  • FIG. 6: oval shape, 2 hole-shaped inlet openings
  • FIG. 7: bone-shaped, 2×3 hole-shaped inlet openings, 1 outlet
  • FIG. 8: bone-shaped, 2×2 hole-shaped inlet openings, asymmetrical, 1 outlet
  • FIG. 9: figure-of-eight shape, 2×3 hole-shaped inlet openings, 1 outlet
  • FIG. 10: figure-of-eight shape, 2×2 hole-shaped inlet openings, asymmetrical, 1 outlet
  • FIG. 11: teardrop-shape, 3 hole-shaped inlet openings, 1 outlet
  • FIG. 12: teardrop-shape, 4 hole-shaped inlet openings, 1 outlet
  • FIG. 13: teardrop-shape, crescent-shaped inlet, 1 outlet
    • DETAILED DESCRIPTION OF THE INVENTION
  • The invention relates to optimised packages as described above which allow improved air flow and hence improved delivery of a pharmaceutical composition, mixture or formulation by virtue of the shape of their opening pattern in their piercing pattern and the fill level with the pharmaceutical composition, mixture or formulation. Preferably the packages consist of a capsule, a blister, a blister disc or a blister strip. These different forms (with the exception of the capsules) will hereinafter be referred to over all as blisters.
  • The capsule generally consists of two parts, a capsule body (body) and a capsule cap (cap), which fit telescopically inside one another. However, multi-part capsules are also known. It is preferable to use size 2-4 capsules, most preferably size 3 capsules.
  • The capsule material is non-digestible plastics or gelatine, particularly hard gelatine.
  • The blister disc may be, for example, a cylinder-like disc up to 5 mm high and up to 15 cm in diameter. In the disc are depressions or holes (wells) formed perpendicularly to the plane of the disc. A disc of this kind may for example be placed in an inhaler according to DE 3348370 or DE 3336486. An inhaler of this kind has a housing which contains the disc-shaped round blister with medicament pouches packed therein. The inhaler comprises, inter alia, a pin which is arranged so that it can open one medicament pouch, so that the medicament is released into the chamber and can be breathed in through a mouthpiece.
  • The shape of the package according to the invention including the shape of the well is fundamentally determined by the powder inhaler which is to be used. Preferably, the packaging is teardrop-shaped or oval or in the shape of a figure of eight. The inflow surfaces and outflow surface(s) are as far away from one another as possible.
  • The package which is a blister first of all comprises a base element consisting of a thermoplastic plastics and at least two wells separated from one another by a web. The wells are open at least on one side, possible on two opposing sides. These openings are closed off in the packaging ready for use, e.g., by means of a sealing foil which is attached to the base element.
  • The package may consist of standard commercial materials. Preferably, it consists of a plastics material. Most preferably, the materials used as plastics selected from among the thermoplastic polymers such as, e.g., polystyrenes, polyolefins, polyamides, polyvinyl chlorides, polyethylenes, polycarbonate, polyester, polypropylene, polyethylene terephthalate or polyurethane. These have the necessary rigidity or mobility to enable them to perform the mechanical tasks of the primary packaging. Also suitable are, for example, natural substances such as gelatine or composite materials of plastics and metals, such as aluminium.
  • According to the invention it is not essential, though preferable, that all the walls of the well should consist of the same material. In a well, at least the wall that closes off the opening may be made of a different material from the other walls.
  • Further information regarding the composition or processing can be found in the prior art, particularly EP599690, EP432438 or EP400460.
  • The fill level of the pharmaceutical composition, mixture or formulation in the package can be optimised and will depend on the flowability of the pharmaceutical composition, mixture or formulation.
  • The term flowability indicates the ability of the pharmaceutical composition, mixture or formulation to flow easily as a loose material. In the art the flowability ffc is defined as follows:
    ff c=σ1/σc.
  • Here, σ1 is the solidification tension and σc is the bulk strength. Normally the flowability is determined using a ring shear device.
  • For pharmaceutical compositions, mixtures, or formulations with poor to no flowability, the flowability accords with the following: 4≧ffc>1. In this case, packages are used which are partly filled, such that there is a free passage for air between at least one inlet opening and an outlet opening. For readily flowable pharmaceutical compositions, formulations or mixtures the formula for the flowability is 4<ffc. In this case, packages which are partly filled are used, such that there is a free passage of air between at least one inlet opening and an outlet opening, or which are completely filled so that an advantageous (simple and inexpensive) filling process can be used. In the latter case, the fill volume is determined by the shape of the packaging and there is no need for any special metering process.
  • Examples of pharmaceutical compositions, formulations or mixtures include all the inhalable compounds, such as, e.g., inhalable macromolecules, as disclosed in EP 1 003 478.
  • The compounds listed below may be used in the device according to the invention on their own or in combination. In the compounds mentioned below, W is a pharmacologically active substance and is selected (for example) from among the betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, H1-antihistamines, PAF-antagonists, and P13-kinase inhibitors. Moreover, double or triple combinations of W may be combined and used in the device according to the invention. Combinations of W might be, for example:
      • W denotes a betamimetic, combined with an anticholinergic, corticosteroid, PDE4-inhibitor, EGFR-inhibitor or LTD4-antagonist,
      • W denotes an anticholinergic, combined with a betamimetic, corticosteroid, PDE4-inhibitor, EGFR-inhibitor or LTD4-antagonist,
      • W denotes a corticosteroid, combined with a PDE4-inhibitor, EGFR-inhibitor or LTD4-antagonist
      • W denotes a PDE4-inhibitor, combined with an EGFR-inhibitor or LTD4-antagonist
      • W denotes an EGFR-inhibitor, combined with an LTD4-antagonist.
  • The compounds used as betamimetics are preferably compounds selected from among albuterol, arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmefamol, salmeterol, soterenol, sulphonterol, terbutaline, tiaramide, tolubuterol, zinterol, CHF-1035, HOKU-81, KUL-1248, and
      • 3-(4-{6-[2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy}-butyl)-benzyl-sulphonamide
      • 5-[2-(5.6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one
      • 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulphonyl}ethyl]-amino}ethyl]-2(3H)-benzothiazolone
      • 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol
      • 1-[3-(4-methoxybenzyl-amino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol
      • 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol
      • 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol
      • 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]ethanol
      • 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butylamino}ethanol
      • 5-hydroxy-8-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-one
      • 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butylamino)ethanol
      • 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one
      • 6-hydroxy-8-{1-hydroxy-2-[2-(ethyl 4-phenoxy-acetate)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one
      • 6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxy-acetic acid)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one
      • 8-{2-[1,1 -dimethyl-2-(2.4.6-trimethylphenyl)-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one
      • 6-hydroxy-8-{1-hydroxy-2-[2-(4-hydroxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one
      • 6-hydroxy-8-{1-hydroxy-2-[2-(4-isopropyl-phenyl)-1.1dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one
      • 8-{2-[2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one
      • 8-{2-[2-(4-ethoxy-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one
      • 4-(4-{2-[2-hydroxy-2-(6-hydroxy-3-oxo-3.4-dihydro-2H-benzo[1,4]oxazin-8-yl)-ethylamino]-2-methyl-propyl}-phenoxy)-butyric acid
      • 8-{2-[2-(3.4-difluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one
      • 1-(4-ethoxy-carbonylamino-3-cyano-5-fluorophenyl)-2-(tert-butylamino)ethanol
      • 2-hydroxy-5-(1-hydroxy-2-{2-[4-(2-hydroxy-2-phenyl-ethylamino)-phenyl]-ethylamino}-ethyl)-benzaldehyde
      • N-[2-hydroxy-5-(1-hydroxy-2-{2-[4-(2-hydroxy-2-phenyl-ethylamino)-phenyl]-ethylamino}-ethyl)-phenyl]-formamide
      • 8-hydroxy-5-(1-hydroxy-2-{2-[4-(6-methoxy-biphenyl-3-ylamino)-phenyl]-ethylamino}-ethyl)-1H-quinolin-2-one
      • 8-hydroxy-5-[1-hydroxy-2-(6-phenethylamino-hexylamino)-ethyl]-1H-quinolin-2-one
      • 5-[2-(2-{4-[4-(2-amino-2-methyl-propoxy)-phenylamino]-phenyl}-ethylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one
      • [3-(4-{6-[2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy}-butyl)-5-methyl-phenyl]-urea
      • 4-(2-{6-[2-(2.6-dichloro-benzyloxy)-ethoxy]-hexylamino}-1-hydroxy-ethyl)-2-hydroxymethyl-phenol
      • 3-(4-{6-[2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy}-butyl)-benzylsulphonamide
      • 3-(3-{7-[2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-heptyloxy}-propyl)-benzylsulphonamide
      • 4-(2-{6-[4-(3-cyclopentanesulphonyl-phenyl)-butoxy]-hexylamino}-1-hydroxy-ethyl)-2-hydroxymethyl-phenol
      • N-Adamantan-2-yl-2-(3-{2-[2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-propyl}-phenyl)-acetamide optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof. According to the invention the acid addition salts of the betamimetics are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
  • The anticholinergics used are preferably compounds selected from among the tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, trospium salts, preferably the chloride salt, tolterodine. In the above-mentioned salts the cations are the pharmacologically active constituents. As anions the above-mentioned salts may preferably contain the chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulphonate, while chloride, bromide, iodide, sulphate, methanesulphonate or p-toluenesulphonate are preferred as counter-ions. Of all the salts the chlorides, bromides, iodides, and methanesulphonates are particularly preferred.
  • Other preferred anticholinergics are selected from among the salts of formula AC-1
    Figure US20070221535A1-20070927-C00001
    wherein X− denotes an anion with a single negative charge, preferably an anion selected from among the fluoride, chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, preferably an anion with a single negative charge, particularly preferably an anion selected from among the fluoride, chloride, bromide, methanesulphonate and p-toluenesulphonate, particularly preferably bromide, optionally in the form of the racemates, enantiomers or hydrates thereof. Of particular importance are those pharmaceutical combinations which contain the enantiomers of formula AC-1-en
    Figure US20070221535A1-20070927-C00002
    wherein X− may have the above-mentioned meanings. Other preferred anticholinergics are selected from the salts of formula AC-2
    Figure US20070221535A1-20070927-C00003
    wherein R denotes either methyl or ethyl and wherein X−may have the above-mentioned meanings. In an altemativen embodiment the compound of formula AC-2 may also be present in the form of the free base AC-2-base.
    Figure US20070221535A1-20070927-C00004
  • Other specified compounds are:
      • tropenol 2,2-diphenylpropionate methobromide,
      • scopine 2,2-diphenylpropionate methobromide,
      • scopine 2-fluoro-2,2-diphenylacetate methobromide,
      • tropenol 2-fluoro-2,2-diphenylacetate methobromide;
      • tropenol 3,3′,4,4′-tetrafluorobenzilate methobromide,
      • scopine 3,3′,4,4′-tetrafluorobenzilate methobromide,
      • tropenol 4,4′-difluorobenzilate methobromide,
      • scopine 4,4′-difluorobenzilate methobromide,
      • tropenol 3,3′-difluorobenzilate methobromide,
      • scopine 3,3′- difluorobenzilate methobromide;
      • tropenol 9-hydroxy-fluorene-9-carboxylate methobromide;
      • tropenol 9-fluoro-fluorene-9-carboxylate methobromide;
      • scopine 9-hydroxy-fluorene-9-carboxylate methobromide;
      • scopine 9-fluoro-fluorene-9-carboxylate methobromide;
      • tropenol 9-methyl-fluorene-9-carboxylate methobromide;
      • scopine 9-methyl-fluorene-9-carboxylate methobromide;
      • cyclopropyltropine benzilate methobromide;
      • cyclopropyltropine 2,2-diphenylpropionate methobromide;
      • cyclopropyltropine 9-hydroxy-xanthene-9-carboxylate methobromide;
      • cyclopropyltropine 9-methyl-fluorene-9-carboxylate methobromide;
      • cyclopropyltropine 9-methyl-xanthene-9-carboxylate methobromide;
  • cyclopropyltropine 9-hydroxy-fluorene-9-carboxylate methobromide;
      • cyclopropyltropine methyl 4,4′-difluorobenzilate methobromide.
      • tropenol 9-hydroxy-xanthene-9-carboxylate methobromide;
      • scopine 9-hydroxy-xanthene-9-carboxylate methobromide;
      • tropenol 9-methyl-xanthene-9-carboxylate -methobromide;
      • scopine 9-methyl-xanthene-9-carboxylate -methobromide;
      • tropenol 9-ethyl-xanthene-9-carboxylate methobromide;
      • tropenol 9-difluoromethyl-xanthene-9-carboxylate methobromide;
      • scopine 9-hydroxymethyl-xanthene-9-carboxylate methobromide,
  • The above-mentioned compounds may also be used as salts within the scope of the present invention, wherein instead of the methobromide the salts metho-X are used, wherein X may have the meanings given hereinbefore for X−.
  • As corticosteroids it is preferable to use compounds selected from among beclomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone, RPR-106541, NS-126, ST-26, and
      • (S)-fluoromethyl 6,9-difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxo-androsta-1,4-diene-17-carbothionate
      • (S)-(2-oxo-tetrahydro-furan-3S-yl)6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-propionyloxy-androsta-1,4-diene-17-carbothionate,
      • cyanomethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-(2,2,3,3-tertamethylcyclopropylcarbonyl)oxy-androsta-1,4-diene-17β-carboxylate optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the salts and derivatives thereof, the solvates and/or hydrates thereof. Any reference to steroids includes a reference to any salts or derivatives, hydrates or solvates thereof which may exist. Examples of possible salts and derivatives of the steroids may be: alkali metal salts, such as for example sodium or potassium salts, sulphobenzoates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates, or furoates.
  • PDE4-inhibitors which may be used are preferably compounds selected from among enprofyllin, theophyllin, roflumilast, ariflo (cilomilast), tofimilast, pumafentrin, lirimilast, arofyllin, atizoram, D-4418, Bay-198004, BY343, CP-325.366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-11294A, C1-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370, and
      • N-(3,5-dichloro-1-oxo-pyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide
      • (−)p-[(4αR*,10bS*)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[s][1,6]naphthyridin-6-yl]-N,N-diisopropylbenzamide
      • (R)-(+)-1-(4-bromobenzyl)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone
      • b 3-(cyclopentyloxy-4-methoxyphenyl)-1-(4-N′-[N-2-cyano-S-methyl-isothioureido]benzyl)-2-pyrrolidone
      • cis[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid]
      • 2-carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)cyclohexan-1-one
      • cis[4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-ol]
      • (R)-(+)-ethyl[4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-ylidene]acetate
      • (S)-(−)-ethyl[4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-ylidene]acetate
      • 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9H-pyrazolo[3.4-c]-1,2,4-triazolo[4.3-a]pyridine
      • 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(tert-butyl)-9H-pyrazolo[3.4-c]-1,2,4-triazolo[4.3-a]pyridine
        optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts thereof, the solvates and/or hydrates thereof. According to the invention the acid addition salts of the PDE4 inhibitors are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate, and hydro-p-toluenesulphonate.
  • The LTD4-antagonists used are preferably compounds selected from among montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001,MEN-91507 (LM-1507), VUF-5078, VUF-K-8707, L-733321 and
      • 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio)methylcyclopropane-acetic acid,
      • 1-(((1(R)-3(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yI)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
      • [2-[[2-(4-tert-butyl-2-thiazolyl)-5-benzofuranyl]oxymethyl]phenyl]acetic acid optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates and/or hydrates thereof. According to the invention these acid addition salts are preferably selected from among the hydrochloride, hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate, and hydro-p-toluenesulphonate. By salts or derivatives which the LTD4-antagonists may optionally be capable of forming are meant, for example: alkali metal salts, such as for example sodium or potassium salts, alkaline earth metal salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates, or furoates.
  • EGFR-inhibitors which may be used are preferably compounds selected from among cetuximab, trastuzumab, ABX-EGF, Mab ICR-62, and
      • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1 -yl]amino}-7-cyclopropylmethoxy-quinazoline
      • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]-amino}-7-cyclopropylmethoxy-quinazoline
      • 4-[(3 -chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline
      • 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline
      • 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(N,N-bis-(2-methoxy-ethyl)-amino)-1-oxo-2-buten1-yl]amino}-7-cyclopropylmethoxy-quinazoline
      • 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-ethyl-amino]-1-oxo-2-buten-1-yl} amino)-7-cyclopropylmethoxy-quinazoline
      • 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline amino }-7-cyclopentyloxy-quinazoline
      • 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline
      • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((R)-tetrahydrofuran-3-yloxy)-quinazo line
      • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazo line
      • 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopentyloxy-quinazoline
      • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline
      • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline
      • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydro furan-2-yl)methoxy]-quinazo line
      • 4-[(3-ethynyl-phenyl)amino]-6.7-bis-(2-methoxy-ethoxy)-quinazoline
      • 4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)-propyloxy]-6-[(vinyl-carbonyl)amino]-quinazoline
      • 4-[(R)-(1-phenyl-ethyl)amino]-6-(4-hydroxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidine
      • 3-cyano-4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-ethoxy-quinoline
      • 4-{[3-chloro-4-(3-fluoro-benzyloxy)-phenyl]amino }-6-(5-{[(2-methanesulphonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline
      • 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline
      • 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N,N-bis-(2-methoxy-ethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline
      • 4-[(3-ethynyl-phenyl)amino]-6-{[4-(5.5-dimethyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2.2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2.2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-(2.2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-6-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{2-[4-(2-oxo-morpholin-4-yl)-piperidin-1-yl]-ethoxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(tert.-butyloxycarbonyl)-piperidin-4-yloxy]-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-amino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methanesulphonylamino-cyclohexan-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-3-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{ 1-[(methoxymethyl)carbonyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-3-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-acetylamino-ethyl)-piperidin-4-yloxy]-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-ethoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-hydroxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(dimethylamino)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-acetylamino-ethoxy)-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methanesulphonylamino-ethoxy)-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1 -[(piperidin-1-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-aminocarbonylmethyl-piperidin-4-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(tetrahydropyran-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazo line
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(morpholin-4-yl)sulphonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-ethansulphonylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-ethoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-methoxy-acetyl)-piperidin-4-yloxy]-7-(2-methoxy-ethoxy)-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-acetylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
      • 4-[(3-ethynyl-phenyl)amino]-6-[1-(tert.-butyloxycarbonyl)-piperidin-4-yloxy]-7-methoxy-quinazoline
      • 4-[(3-ethynyl-phenyl)amino]-6-(tetrahydropyran-4-yloxy]-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(piperidin-1-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazo line
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(4-methyl-piperazin-1-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazo line
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(2-oxopyrrolidin-1-yl)ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-(2-methoxy-ethoxy)-quinazoline
      • 4-[(3-ethynyl-phenyl)amino]-6-(1-acetyl-piperidin-4-yloxy)-7-methoxy-quinazoline
      • 4-[(3-ethynyl-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline
      • 4-[(3-ethynyl-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7(2-methoxy-ethoxy)-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-isopropyloxycarbonyl-piperidin-4-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[N-(2-methoxy-acetyl)-N-methyl-amino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline
      • 4-[(3-ethynyl-phenyl)amino]-6-(piperidin-4-yloxy)-7-methoxy-quinazoline
      • 4-[(3-ethynyl-phenyl)amino]-6-[1-(2-methoxy-acetyl)-piperidin-4-yloxy]-7-methoxy-quinazoline
      • 4-[(3-ethynyl-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(cis-2,6-dimethyl-morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(2-methyl-morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(S,S)-(2-oxa-5-aza-bicyclo[2,2, 1 ]hept-5-yl)carbonyl]-piperidin-4-yloxy }-7-methoxy-quinazo line
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(N-methyl-N-2-methoxyethyl-amino)carbonyl]-pip eridin-4-yloxy}-7-methoxy-quinazo line
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-ethyl-piperidin-4-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(2-methoxyethyl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(3-methoxypropyl-amino)-carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2.2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline
      • 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline
        optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof. According to the invention these acid addition salts are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate, and hydro-p-toluenesulphonate.
  • The dopamine agonists used are preferably compounds selected from among bromocriptin, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexol, roxindol, ropinirol, talipexol, tergurid, and viozan, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof. According to the invention these acid addition salts are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate, and hydro-p-toluenesulphonate.
  • H1-Antihistamines which may be used are preferably compounds selected from among epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bamipine, cexchlorpheniramine, pheniramine, doxylamine, chlorophenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine, and meclozine, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates, or hydrates thereof. According to the invention these acid addition salts are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate, and hydro-p-toluenesulphonate.
  • It is also possible to use inhalable macromolecules, as disclosed in EP 1 003 478.
  • In addition, the compounds may come from the groups of ergot alkaloid derivatives, the triptans, the CGRP-inhibitors, the phosphodiesterase-V inhibitors, optionally in the form of the racemates, enantiomers, or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts, the solvates, and/or hydrates thereof.
  • Examples of ergot alkaloid derivatives are dihydroergotamine and ergotamine.
  • For inhalation, suitable substances include pharmaceutical compositions, pharmaceutical formulations and mixtures with the above-mentioned active substances, as well as the salts and esters thereof and combinations of these active substances, salts, and esters.
    • EXAMPLE
  • The emptying properties were determined using a standard powder (glass beads) by measuring the time taken for emptying a given constant flow by volume (corresponding to 10 L/min of air). Table 1 shows the emptying time of the different shapes of capsules or blisters. The inlet openings are shown in the drawings as small circles while the outlet openings are shown as large circles.
    TABLE 1
    type name emptying time (s)
    1 sphere or hemisphere, 5 inlets >100
    2 sphere or hemisphere, 4 inlets >100
    3 oval shape, 6 inlets 57
    4 oval shape, 5 inlets, asymmetrical 10
    5 oval shape, 3 inlets, asymmetrical 2.2
    6 oval shape, 2 holes >100
    7 bone, 2 × 3 inlets 38
    8 bone, 2 × 2 inlets, asymmetrical 2.7
    9 figure-of-eight, 2 × 3 inlets >100
    10 figure-of-eight, 2 × 2 inlets, asymmetrical >100
    11 teardrop, 3 inlets 2.9
    12 teardrop, 4 inlets 2.4
    13 teardrop, crescent-shaped inlet 1.7
  • The results in Table 1 show that the emptying properties of a package depend to a considerable extent on its shape and opening or openings.
    TABLE 2
    residue after emptying (%) emptying time (seconds)
    fenoterol tiotropium fenoterol tiotropium
    micronised powder powder micronised powder powder
    Name fenoterol mixture mixture fenoterol mixture mixture
    1 88.63 84.02 46.896 8.46 7.91 6.8
    2 87.04 87.58 45.832 9.35 7.42 6.44
    3 52.95 39.28 13.936 4.29 3.13 3.46
    4 29.93 23.49 5.744 1.19 1.27 1.66
    5 32.88 16.37 11.408 1.2 1.31 1.03
    6 80.25 71.81 33.816 6.95 6.53 5.63
    7 51.37 33.93 20.56 3.95 3.18 2.92
    8 38.39 19.33 13.216 1.71 1.41 0.86
    9 71.6 57.52 31.56 5.7 4.76 4.23
    10 68.69 54.36 28.608 5.85 4.03 5.24
    11 38.07 22.15 8.304 2.21 1.82 0.93
    12 37.73 9.78 6.984 1.85 1.27 0.3
    13 34.36 10.81 5.12 0.69 0.35 0.6
  • The flow rate of the air through the package of standard commercial size: 10 litres per minutes
  • The active substance in micronised form has a particle size of 1-5 μm. As well as the active substance the powder mixture also contains lactose 200 m.
  • The results of Table 2 show, for the active substances fenoterol and tiotropium
      • a) the residue left in the well, and
      • b) the emptying time of the well.
  • A well of a package which has an optimum air flow by reason of its shape and opening patter has significantly enhanced emptying properties. The following formula applies to the ratio V (sum of the inflow surfaces divided by the sum of the outflow surfaces): 0.5<V<2. Preferably the sum of the inflow surfaces should be equal to the sum of the outflow surfaces.

Claims (18)

1. A package for use in a powder inhaler, the package being optimised in its shape and in the fill level to a pharmaceutical composition, mixture, or formulation and adapted to be opened in such a way that the delivery of the pharmaceutical composition, mixture, or formulation is optimised, wherein the package is a capsule or a blister, a blister disc, a blister coil, or a blister strip with one or more wells, and wherein, per capsule or well, the sum of the inflow surfaces is equal to the sum of the outflow surface or surfaces per well or capsule.
2. The package according to claim 1, wherein the package is a capsule.
3. The package according to claim 2, wherein the package is a size 2-4 capsule.
4. The package according to claim 2, wherein the package is a size 3 capsule.
5. The package according to claim 1, wherein the well or capsule is teardrop-shaped and the inflow surfaces and the outflow surface or surfaces are at the maximum spacing from one another.
6. The package according to claim 1, wherein the well or capsule is oval in shape and the inflow surfaces and the outflow surface or surfaces are at the maximum spacing from one another.
7. The package according to claim 1, wherein the well or capsule is in the form of a figure-of-eight and the inflow surfaces and the outflow surface or surfaces are at the maximum spacing from one another.
8. The package according to claim 1, wherein the well or capsule has a shape as shown in any one of FIGS. 1-13.
9. The package according to claim 1, wherein the well or capsule has an opening pattern as shown in any one of FIGS. 1-13.
10. A powder inhaler comprising a package that is optimised in its shape and in the fill level to a pharmaceutical composition, mixture, or formulation and adapted to be opened in such a way that the delivery of the pharmaceutical composition, mixture, or formulation is optimised, wherein the package is a capsule or a blister, a blister disc, a blister coil, or a blister strip with one or more wells, and wherein, per capsule or well, the sum of the inflow surfaces is equal to the sum of the outflow surface or surfaces per well or capsule.
11. The powder inhaler according to claim 10, wherein the package is a capsule.
12. The powder inhaler according to claim 11, wherein the package is a size 2-4 capsule.
13. The powder inhaler according to claim 11, wherein the package is a size 3 capsule.
14. The powder inhaler according to claim 10, wherein the well or capsule is teardrop-shaped and the inflow surfaces and the outflow surface or surfaces are at the maximum spacing from one another.
15. The powder inhaler according to claim 10, wherein the well or capsule is oval in shape and the inflow surfaces and the outflow surface or surfaces are at the maximum spacing from one another.
16. The powder inhaler according to claim 10, wherein the well or capsule is in the form of a figure-of-eight and the inflow surfaces and the outflow surface or surfaces are at the maximum spacing from one another.
17. The powder inhaler according to claim 10, wherein the well or capsule has a shape as shown in any one of FIGS. 1-13.
18. The powder inhaler according to claim 10, wherein the well or capsule has an opening pattern as shown in any one of FIGS. 1-13.
US11/691,882 2006-03-27 2007-03-27 Package for multiple dose inhalators having optimised emptying properties Abandoned US20070221535A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006014434 2006-03-27
DE102006014434A DE102006014434A1 (en) 2006-03-27 2006-03-27 Packaging for multidose powder inhalers with optimized emptying properties

Publications (1)

Publication Number Publication Date
US20070221535A1 true US20070221535A1 (en) 2007-09-27

Family

ID=38117438

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/691,882 Abandoned US20070221535A1 (en) 2006-03-27 2007-03-27 Package for multiple dose inhalators having optimised emptying properties

Country Status (19)

Country Link
US (1) US20070221535A1 (en)
EP (1) EP2001536A1 (en)
JP (1) JP2009531238A (en)
KR (1) KR20080110866A (en)
CN (1) CN101410147A (en)
AR (1) AR060073A1 (en)
AU (1) AU2007229530A1 (en)
BR (1) BRPI0710106A2 (en)
CA (1) CA2646337A1 (en)
DE (1) DE102006014434A1 (en)
EA (1) EA200801917A1 (en)
EC (1) ECSP088768A (en)
MX (1) MX2008011694A (en)
NO (1) NO20083890L (en)
PE (1) PE20071301A1 (en)
TW (1) TW200803933A (en)
UY (1) UY30234A1 (en)
WO (1) WO2007110402A1 (en)
ZA (1) ZA200807579B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150101595A1 (en) * 2013-10-15 2015-04-16 Mystic Pharmaceuticals, Inc. Controllable Rate Turbulating Nozzle

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3669113A (en) * 1966-03-07 1972-06-13 Fisons Ltd Inhalation device
US3927195A (en) * 1974-01-31 1975-12-16 Lilly Industries Ltd Production of capsules
US3991761A (en) * 1974-03-18 1976-11-16 Salvatore Cocozza Inhaler for powdered medicaments
US5673686A (en) * 1994-02-02 1997-10-07 Plurichemie Anstalt Medicament inhaler and method
US5921236A (en) * 1995-03-10 1999-07-13 Unisia Jecs Corporation Medicine administering device for nasal cavities
US6082356A (en) * 1995-09-04 2000-07-04 Tebro Device for pre-dosing of a powdery product for a product dispenser
US6116238A (en) * 1997-12-02 2000-09-12 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6273086B1 (en) * 1998-02-06 2001-08-14 Unisia Jecs Corporation Inhalant medicator
US20010029947A1 (en) * 1999-12-17 2001-10-18 Steve Paboojian Receptacles to facilitate the extraction of powders
US6328034B1 (en) * 1996-07-22 2001-12-11 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6470884B2 (en) * 1996-01-29 2002-10-29 Aventis Pharma Limited Capsule opening arrangement for use in a powder inhaler
US6543448B1 (en) * 1994-09-21 2003-04-08 Inhale Therapeutic Systems, Inc. Apparatus and methods for dispersing dry powder medicaments
US6810872B1 (en) * 1999-12-10 2004-11-02 Unisia Jecs Corporation Inhalant medicator
US20050019388A1 (en) * 2001-12-11 2005-01-27 Ajinomoto Co., Inc. Edible capsules
WO2005025656A1 (en) * 2003-09-15 2005-03-24 Vectura Limited Dry powder inhaler
US20050061705A1 (en) * 2003-09-18 2005-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical blister
US20050103337A1 (en) * 2003-10-27 2005-05-19 Anthony James Hickey Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances
US20080197045A1 (en) * 2005-07-27 2008-08-21 Burkhard Metzger Medicament Blister
US20090101145A1 (en) * 2006-04-13 2009-04-23 Boehringer Ingelheim International Gmbh Medicaments Magazine, and a Device and Method for Opening it; Multi-Dose Powder Inhaler
US20090250057A1 (en) * 2006-04-13 2009-10-08 Boehringer Ingelheim International Gmbh Medicaments magazine for an inhaler, and a multi-dose powder inhaler

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2340758A (en) * 1998-08-21 2000-03-01 Bespak Plc Drug dispensing system
GB0113881D0 (en) * 2001-06-07 2001-08-01 Innovate Biomed Ltd Foil cutting system

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3669113A (en) * 1966-03-07 1972-06-13 Fisons Ltd Inhalation device
US3927195A (en) * 1974-01-31 1975-12-16 Lilly Industries Ltd Production of capsules
US3991761A (en) * 1974-03-18 1976-11-16 Salvatore Cocozza Inhaler for powdered medicaments
US5673686A (en) * 1994-02-02 1997-10-07 Plurichemie Anstalt Medicament inhaler and method
US6543448B1 (en) * 1994-09-21 2003-04-08 Inhale Therapeutic Systems, Inc. Apparatus and methods for dispersing dry powder medicaments
US5921236A (en) * 1995-03-10 1999-07-13 Unisia Jecs Corporation Medicine administering device for nasal cavities
US6082356A (en) * 1995-09-04 2000-07-04 Tebro Device for pre-dosing of a powdery product for a product dispenser
US6470884B2 (en) * 1996-01-29 2002-10-29 Aventis Pharma Limited Capsule opening arrangement for use in a powder inhaler
US6328034B1 (en) * 1996-07-22 2001-12-11 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6116238A (en) * 1997-12-02 2000-09-12 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6273086B1 (en) * 1998-02-06 2001-08-14 Unisia Jecs Corporation Inhalant medicator
US6810872B1 (en) * 1999-12-10 2004-11-02 Unisia Jecs Corporation Inhalant medicator
US20010029947A1 (en) * 1999-12-17 2001-10-18 Steve Paboojian Receptacles to facilitate the extraction of powders
US20050019388A1 (en) * 2001-12-11 2005-01-27 Ajinomoto Co., Inc. Edible capsules
WO2005025656A1 (en) * 2003-09-15 2005-03-24 Vectura Limited Dry powder inhaler
US20050061705A1 (en) * 2003-09-18 2005-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical blister
US20050103337A1 (en) * 2003-10-27 2005-05-19 Anthony James Hickey Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances
US20080197045A1 (en) * 2005-07-27 2008-08-21 Burkhard Metzger Medicament Blister
US20090101145A1 (en) * 2006-04-13 2009-04-23 Boehringer Ingelheim International Gmbh Medicaments Magazine, and a Device and Method for Opening it; Multi-Dose Powder Inhaler
US20090250057A1 (en) * 2006-04-13 2009-10-08 Boehringer Ingelheim International Gmbh Medicaments magazine for an inhaler, and a multi-dose powder inhaler

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150101595A1 (en) * 2013-10-15 2015-04-16 Mystic Pharmaceuticals, Inc. Controllable Rate Turbulating Nozzle
US10149951B2 (en) * 2013-10-15 2018-12-11 Mystic Pharmaceuticals, Inc. Controllable rate turbulating nozzle

Also Published As

Publication number Publication date
EA200801917A1 (en) 2009-04-28
UY30234A1 (en) 2007-10-31
PE20071301A1 (en) 2008-02-04
BRPI0710106A2 (en) 2011-08-02
CA2646337A1 (en) 2007-10-04
ECSP088768A (en) 2008-10-31
AU2007229530A1 (en) 2007-10-04
EP2001536A1 (en) 2008-12-17
MX2008011694A (en) 2008-09-24
AR060073A1 (en) 2008-05-21
JP2009531238A (en) 2009-09-03
ZA200807579B (en) 2009-10-28
NO20083890L (en) 2008-11-17
TW200803933A (en) 2008-01-16
CN101410147A (en) 2009-04-15
WO2007110402A1 (en) 2007-10-04
AU2007229530A8 (en) 2008-11-13
DE102006014434A1 (en) 2007-10-04
KR20080110866A (en) 2008-12-19

Similar Documents

Publication Publication Date Title
US8561610B2 (en) Medicament dispensing device, medicament magazine therefor and method of removing a medicament from a medicament chamber
US7870856B2 (en) Inhaler
US9259540B2 (en) Nozzle and inhaler and method for producing a nozzle
US8267082B2 (en) Medicaments magazine for an inhaler, and a multi-dose powder inhaler
US20110203586A1 (en) Powder Inhalers
US20090235929A1 (en) Powder inhalers
US8746244B2 (en) Powder inhaler
US8196578B2 (en) Inhaler
US8528548B2 (en) Inhaler
US8205613B2 (en) Piston dosing pump
US20100252032A1 (en) Inhaler
US20070107722A1 (en) Needle for piercing a powder capsule for inhalation
US20100275917A1 (en) Powder inhaler
US9533112B2 (en) Inhaler
US20100059050A1 (en) Mouthpiece for an inhaler
US20100059051A1 (en) Inhaler
US20110036733A1 (en) Packaging Material with Desiccant
US20070221213A1 (en) Dosage aerosols for the application of pharmaceutical formulations
US8944054B2 (en) Medicine dispensation device
US8602024B2 (en) Medicaments magazine, and a device and method for opening it; multi-dose powder inhaler
US20070221535A1 (en) Package for multiple dose inhalators having optimised emptying properties
US20100327476A1 (en) Method and device for filling capsules
US20110223113A1 (en) Propellant for dosing aerosols comprising packagings
US20120285451A1 (en) Two-piece metal capsule for accommodating pharmaceutical preparations for powder inhalers

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION